摘要
目的:探讨托伐普坦片联合左西孟旦注射液治疗顽固性心力衰竭的临床疗效。方法:选择深圳市罗湖区中医院2015年1月—2016年1月收治的106例顽固性心力衰竭患者,按照随机数字法分为观察组和对照组,每组各53例。对照组患者在常规治疗的基础上给予单纯托伐普坦片,观察组患者在对照组治疗的基础上联合应用左西孟旦注射液。观察2组患者的疗效、不良反应及心功能改善情况,用药期间监测患者心胸比率(CTR)、心脏指数(CI)等指标。结果:观察组患者的总有效率为94.34%(50/53),对照组为84.91%(45/53),2组的差异有统计学意义(P<0.05)。治疗后,2组患者心功能各指标均较治疗前明显改善,且观察组改善程度明显优于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患者CTR为(0.52±0.06),显著低于对照组的(0.55±0.08);观察组患者的CI为(2.2±0.23)L/(min·m2),显著高于对照组的(1.9±0.2)L/(min·m2),差异有统计学意义(P<0.05)。2组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:托伐普坦片联合左西孟旦注射液治疗顽固性心力衰竭效果较好,能快速改善患者心功能,且不良反应较少。
OBJECTIVE： To probe into the clinical efficacy of tolvaptan combined with levosimendan in treatment of intractable heart failure. METHODS： 106 patients with intractable heart failure admitted into Shenzhen Luohu District Traditional Chinese Medicine Hospital from Jan. 2015 to Jan. 2016 were selected to be divided into observation group and control group via the random number table,with 53 cases in each. The control group were treated with simple tolvaptan on the basis of routine treatment,while the observation group additionally received levosimendan based on the control group. The efficacy,adverse drug reactions and improvement of cardiac function in two groups were observed; and the chest ratio（ CTR）,cardiac index（ CI） were monitored during treatment.RESULTS： The total effective rate of observation group was 94. 34%（ 50 /53）,and control was 84. 91%（ 45 /53）,with statistically significant difference（ P〈0. 05）. After treatment,the improvement of cardiac function in two groups was significantly better than that before treatment,and the observation group was better than that of the control group,the difference was statistically significant（ P〈0. 05）. After treatment,the CTR of patients in observation group was（ 0. 52 ± 0. 06）,which was significantly lower than that of control group（ 0. 55 ± 0. 08）,the difference was statistically significant（ P〈0. 05）. Meanwhile,the CI of patients in observation group was（ 2. 2 ± 0. 23） L /（ min·m2）,which was significantly higher than that of control group（ 1. 9 ± 0. 2） L /（ min·m2）,and the difference was statistically significant（ P〈0. 05）. There was no significance between two groups in the incidence of adverse drug reactions（ P〈0. 05）. CONCLUSIONS： The effects of tolvaptan combined with levosimendan in treatment of intractable heart failure is significant,which can improve the patients of heart function with few adverse drug reactions.
出处
《中国医院用药评价与分析》
2016年第9期1178-1180,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
